HeartBeam Partners With Mount Sinai to Advance AI-ECG Algorithm Development for Remote Cardiac Monitoring

HeartBeam Inc. has entered a strategic collaboration with the Icahn School of Medicine at Mount Sinai to accelerate the joint development and validation of next-generation AI-ECG algorithms. This partnership combines HeartBeam's patented ECG platform, which captures the heart's electrical activity from three non-coplanar dimensions, with Mount Sinai's clinically annotated 12-lead ECG datasets and artificial intelligence expertise. The collaboration leverages longitudinal, high-fidelity synthesized 12-lead ECG data collected from patients in home settings alongside Mount Sinai's clinical data resources to advance AI-driven cardiac monitoring.

The initiative aims to accelerate the training and validation of AI models designed to support personalized cardiac insights, expand potential clinical indications, and enable broader applications in preventive cardiology, chronic disease management, and remote patient monitoring. HeartBeam's technology represents a significant advancement in cardiac care, as it creates the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence.

Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities, potentially redefining the future of cardiac health management. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to technology enablement, with detailed information about the cleared indications available at https://www.heartbeam.com/indications.

The collaboration's importance lies in its potential to transform cardiac care delivery by enabling more accurate remote monitoring and early intervention. By combining HeartBeam's innovative 3D ECG capture technology with Mount Sinai's extensive clinical data and AI expertise, the partnership could lead to more sophisticated algorithms that detect subtle cardiac abnormalities earlier than traditional methods. This advancement could significantly impact preventive cardiology by identifying at-risk patients before major cardiac events occur, potentially reducing hospitalizations and improving patient outcomes through timely intervention.

Remote patient monitoring represents a growing area of healthcare innovation, particularly valuable for managing chronic cardiac conditions where continuous monitoring can prevent complications. The integration of AI with ECG data analysis could enable more personalized treatment approaches based on individual patient patterns rather than population averages. This collaboration between a medical technology company and a leading academic medical center exemplifies how industry-academic partnerships can accelerate medical innovation by combining technological expertise with clinical research capabilities.